Clinical and Survival Insights into Carcinoma Penis: A Retrospective Analysis at a Tertiary Care Facility

Santosh Kumar Swain; Lalatendu Moharana; Ghanashyam Biswas; Lipsita Samantaray; Ayush Dubey; Reetu Singhal; Bhavya Inimerla; Antara Sanyal; Swati Sucharita Mohanty; Soumya Surath Panda

doi:10.1055/s-0045-1809352

South Asian Journal of Cancer, Inhaltsverzeichnis

CC BY-NC-ND 4.0 · South Asian J Cancer
DOI: 10.1055/s-0045-1809352

Original Article

Clinical and Survival Insights into Carcinoma Penis: A Retrospective Analysis at a Tertiary Care Facility

Authors

Santosh Kumar Swain

¹Department of Medical Oncology, Institute of Medical Sciences and Sum Hospital, Siksha ‘O’ Anusandhan Deemed to be University, Bhubaneswar, Odisha, India
Lalatendu Moharana

¹Department of Medical Oncology, Institute of Medical Sciences and Sum Hospital, Siksha ‘O’ Anusandhan Deemed to be University, Bhubaneswar, Odisha, India
Ghanashyam Biswas

¹Department of Medical Oncology, Institute of Medical Sciences and Sum Hospital, Siksha ‘O’ Anusandhan Deemed to be University, Bhubaneswar, Odisha, India
Lipsita Samantaray

¹Department of Medical Oncology, Institute of Medical Sciences and Sum Hospital, Siksha ‘O’ Anusandhan Deemed to be University, Bhubaneswar, Odisha, India
Ayush Dubey

¹Department of Medical Oncology, Institute of Medical Sciences and Sum Hospital, Siksha ‘O’ Anusandhan Deemed to be University, Bhubaneswar, Odisha, India
Reetu Singhal

¹Department of Medical Oncology, Institute of Medical Sciences and Sum Hospital, Siksha ‘O’ Anusandhan Deemed to be University, Bhubaneswar, Odisha, India
Bhavya Inimerla

¹Department of Medical Oncology, Institute of Medical Sciences and Sum Hospital, Siksha ‘O’ Anusandhan Deemed to be University, Bhubaneswar, Odisha, India
Antara Sanyal

¹Department of Medical Oncology, Institute of Medical Sciences and Sum Hospital, Siksha ‘O’ Anusandhan Deemed to be University, Bhubaneswar, Odisha, India
Swati Sucharita Mohanty

¹Department of Medical Oncology, Institute of Medical Sciences and Sum Hospital, Siksha ‘O’ Anusandhan Deemed to be University, Bhubaneswar, Odisha, India
Soumya Surath Panda

¹Department of Medical Oncology, Institute of Medical Sciences and Sum Hospital, Siksha ‘O’ Anusandhan Deemed to be University, Bhubaneswar, Odisha, India

Abstract

Objective

The main objective was to evaluate key survival results, comprising progression-free survival (PFS) and overall survival (OS), in individuals with histopathologically confirmed penile cancer, along with an assessment of clinical features, treatment strategies, and therapy-related side effects.

Materials and Methods

This study comprised retrospective analyses of individuals diagnosed with penile cancer, confirmed by histology, between April 2021 and December 2024, regardless of disease stage. Case records were reviewed to gather information on demographics, clinical details, histopathology, and treatment outcomes.

Statistical Analysis

As the data was collected retrospectively, no prior sample size estimate was performed. Data analysis was carried out using SPSS version 27.

Results

The most common presenting symptoms were ulcerative-proliferative growth (60%), pain (50%), dysuria (40%), and lymphedema (40%). The median age of patients in this retrospective study was 56 years (interquartile range: 49.25–59.25). Out of the 10 patients included, 9 (90%) had localized or locally advanced disease and underwent primary surgical treatment. Among them, eight patients (80%) had partial penectomy, while one patient (10%) underwent total penectomy. These patients received adjuvant chemotherapy and/or radiotherapy based on their disease stage. One patient (10%) had metastatic disease at diagnosis and was treated with upfront palliative chemotherapy. Most patients presented with advanced-stage tumors, with 60% having T3/T4 disease and 90% showing lymph node involvement (N + ). For those with nonmetastatic disease, the median disease-free survival was 14 months (95% confidence interval [CI]: 12.61–15.38). Following disease progression, patients were treated with palliative intent, achieving a median PFS of 12 months (95% CI: 11.29–12.71) and a median OS of 28 months (95% CI: 24.9–31.09). Two patients (20%) experienced grade 3 or higher neutropenia, and one patient had hypothyroidism.

Conclusion

In India, penile cancer is frequently identified at an advanced stage. Patients presenting with recurrent, metastatic, or nodal disease tend to have poor OS, even with optimal palliative systemic therapy. This highlights a significant unmet need for more effective systemic treatment options in this group. Our study underscores the pressing need for region-specific research and improved access to multidisciplinary care.

Keywords

clinical profile - survival - carcinoma penis - overall survival - disease-free survival - progression-free survival

Volltext

Referenzen

References
1 Montes Cardona CE, García-Perdomo HA. Incidence of penile cancer worldwide: systematic review and meta-analysis. Rev Panam Salud Publica 2017; 41: e117
2 Mathur P, Sathishkumar K, Chaturvedi M. et al; ICMR-NCDIR-NCRP Investigator Group. Cancer Statistics, 2020: report from National Cancer Registry Programme, India. JCO Glob Oncol 2020; 6 (06) 1063-1075
3 Garg V, Ray M, Haresh KP. et al. Clinical profile and predictors of survival in carcinoma penis patients. Curr Oncol 2023; 30 (05) 4563-4574
4 Sanchez DF, Soares F, Alvarado-Cabrero I. et al. Pathological factors, behavior, and histological prognostic risk groups in subtypes of penile squamous cell carcinomas (SCC). Semin Diagn Pathol 2015; 32 (03) 222-231
5 Dillner J, von Krogh G, Horenblas S, Meijer CJLM. Etiology of squamous cell carcinoma of the penis. Scand J Urol Nephrol Suppl 2000; 34 (205) 189-193
6 Yuvaraja TB, Waigankar S, Bakshi G, Prakash G. Genitourinary cancers: summary of Indian data. South Asian J Cancer 2016; 5 (03) 122-124
7 Pandey D, Mahajan V, Kannan RR. Prognostic factors in node-positive carcinoma of the penis. J Surg Oncol 2006; 93 (02) 133-138
8 Djajadiningrat RS, Bergman AM, van Werkhoven E, Vegt E, Horenblas S. Neoadjuvant taxane-based combination chemotherapy in patients with advanced penile cancer. Clin Genitourin Cancer 2015; 13 (01) 44-49
9 Sharma P, Djajadiningrat R, Zargar-Shoshtari K. et al. Adjuvant chemotherapy is associated with improved overall survival in pelvic node-positive penile cancer after lymph node dissection: a multi-institutional study. Urol Oncol 2015; 33 (11) 496.e17-496.e23
10 Patil VM, Noronha V, Joshi A. et al. Palliative chemotherapy in carcinoma penis: does platinum and taxane combination holds a promise?. Urol Ann 2014; 6 (01) 18-22
11 Mailankody S, Radhakrishnan V, Raja A, Ganesan TS, Dhanushkodi M, Sagar TG. Outcomes with chemotherapy in carcinoma penis: experience from a tertiary cancer center. Indian J Cancer 2023; 60 (03) 396-402
12 Shah AA, Shah HA, Panjwani GN, Pandey BB, Shah N. Prognostic factors and 5-year survival of patients with carcinoma penis: tertiary health center study. Indian J Cancer 2016; 53 (02) 309-312
13 Noronha V, Kapu V, Joshi A. et al. Clinical profile and outcomes of carcinoma penis patients receiving systemic therapy at an Indian tertiary care center: a retrospective observational study. Clin Genitourin Cancer 2024; 22 (03) 102053
14 Maden C, Sherman KJ, Beckmann AM. et al. History of circumcision, medical conditions, and sexual activity and risk of penile cancer. J Natl Cancer Inst 1993; 85 (01) 19-24
15 Vieira CB, Feitoza L, Pinho J. et al. Profile of patients with penile cancer in the region with the highest worldwide incidence. Sci Rep 2020; 10 (01) 2965
16 Sirithanaphol W, Sookprasert A, Rompsaithong U, Kiatsopit P, Wirasorn K, Chindaprasirt J. Prognostic factors for penile cancer and survival in response to multimodality therapy. Res Rep Urol 2020; 12: 29-34